SIERRA ONCOLOGY, INC. (NASDAQ:SRRA) Files An 8-K Results of Operations and Financial Condition
Item2.02. Results of Operations and Financial Condition.
On May9, 2017, Sierra Oncology, Inc. (the Company) reported its
financial results for the quarter ended March31, 2017. A copy of
the press release issued by the Company is furnished as Exhibit
99.1 to this report.
The information furnished with Item 2.02 of this report,
including Exhibit 99.1, shall not be deemed filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference into
any other filing under the Exchange Act or under the Securities
Act of 1933, as amended, except as expressly set forth by
specific reference in such a filing.
Item9.01. Financial Statements and Exhibits.
|
Exhibit Number |
Description |
|
| 99.1 | Press release dated May9, 2017. |
2
About SIERRA ONCOLOGY, INC. (NASDAQ:SRRA)
Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7. SIERRA ONCOLOGY, INC. (NASDAQ:SRRA) Recent Trading Information
SIERRA ONCOLOGY, INC. (NASDAQ:SRRA) closed its last trading session down -0.03 at 1.33 with 147,526 shares trading hands.
